Guardant Health, Inc. announced the launch of Guardant360 Tissue, a new molecular profiling test for tumor tissue. This test is the first to incorporate comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data, to provide a more complete view of cancer.
Powered by the Guardant Infinity smart liquid biopsy platform, Guardant360 Tissue offers insights beyond conventional genomic sequencing. It requires 92% less tissue surface area for analysis than the industry norm, addressing the challenge of limited or insufficient tissue samples.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated that this test establishes a new standard in tissue molecular profiling, enabling insights across additional dimensions for biopharma and oncologists. Test results are available in less than two weeks and are covered by Medicare for eligible patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.